Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Equity (2016 - 2026)

Intellia Therapeutics has reported Return on Equity over the past 11 years, most recently at 0.01% for Q1 2026.

  • Quarterly Return on Equity changed 0.0% to 0.01% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Equity was 0.01% for Q1 2026 at Intellia Therapeutics, down from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.0% in Q1 2023 and troughed at 0.01% in Q2 2025.
  • The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
  • The largest YoY upside for Return on Equity was 0bps in 2022 against a maximum downside of 0bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then fell by -2bps to 0.0% in 2023, then dropped by -19bps to 0.01% in 2024, then decreased by -9bps to 0.01% in 2025, then decreased by -5bps to 0.01% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Return on Equity are 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).